CATABASIS PHARMACEUTICALS IN's ticker is and the CUSIP is 14875P206. A total of 26 filers reported holding CATABASIS PHARMACEUTICALS IN in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $25,000 | +56.2% | 8,676 | +13.7% | 0.00% | – |
| Q4 2020 | $16,000 | -92.2% | 7,629 | -76.9% | 0.00% | – |
| Q3 2020 | $204,000 | -17.1% | 32,970 | -13.8% | 0.00% | – |
| Q2 2020 | $246,000 | +2136.4% | 38,266 | +2643.1% | 0.00% | – |
| Q2 2019 | $11,000 | +37.5% | 1,395 | +43.8% | 0.00% | – |
| Q1 2019 | $8,000 | -42.9% | 970 | -68.6% | 0.00% | – |
| Q4 2018 | $14,000 | – | 3,090 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eversept Partners, LP | 522,042 | $1,117,170 | 0.13% |
| XTX MARKETS LLC | 26,041 | $56,000 | 0.12% |
| Samsara BioCapital, LLC | 300,000 | $642,000 | 0.06% |
| Ikarian Capital, LLC | 650,000 | $1,392,000 | 0.06% |
| Opaleye Management Inc. | 187,750 | $402,000 | 0.05% |
| SABBY MANAGEMENT, LLC | 108,026 | $231,000 | 0.04% |
| Anson Funds Management LP | 97,601 | $209,000 | 0.04% |
| Virtu Financial LLC | 83,221 | $178,000 | 0.02% |
| GSA CAPITAL PARTNERS LLP | 47,084 | $101,000 | 0.02% |
| WEXFORD CAPITAL LP | 19,512 | $42,000 | 0.01% |